Learn More
We consider panel count data which are frequently obtained in prospective studies involving recurrent events that are only detected and recorded at periodic assessment times. The data take the form of counts of the cumulative number of events detected at each inspection time, along with explanatory covariates. Examples arise in diverse areas such as(More)
Panel count data often occur in long-term studies that concern occurrence rate of a recurrent event. Methods have been proposed for regression analysis of panel count data, but most of the existing research focuses on situations where observation times are independent of longitudinal response variables and therefore rely on conditional inference procedures(More)
P-glycoprotein (P-gp) is an ATP-dependent efflux transporter highly expressed in gastrointestinal tract and multidrug resistance tumor cells. Inhibition or induction of P-gp can cause drug-drug interactions and thus influence the effects of P-gp substrate drugs. Previous studies indicated that 20(S)-ginsenoside Rh2 [20(S)-Rh2] could synergistically enhance(More)
Astragaloside-IV (3-O-beta-d-xylopyranosyl-6-O-beta-d-glucopyranosyl-cycloastragenol) is the major active constituent contained in Radix Astragali. This paper describes a rapid, sensitive and specific assay for quantitative determination of astragaloside-IV in rat plasma. After a liquid/liquid extraction (LLE) with n-butanol and high-performance liquid(More)
The potential for herb-drug interactions has recently received greater attention worldwide, considering the fact that the use of herbal products becomes more and more widespread. The goal of this work was to examine the potential for the metabolism-based drug interaction arising from seven active components (danshensu, protocatechuic aldehyde,(More)
Although dexibuprofen (S-ibuprofen) was marketed in Austria and Switzerland, the racemate at various formulations is still extensively used worldwide, and there are no indications that the racemate will be replaced by the single enantiomer. Thus, elucidation of the characteristics and involved mechanisms of the chiral pharmacokinetics of racemic ibuprofen(More)
Edaravone was launched in Japan in 2001 and was the first neuroprotectant developed for the treatment of acute cerebral infarction. Edaravone is mainly eliminated as glucuronide conjugate in human urine (approximately 70%), but the mechanism involved in the elimination pathway remains unidentified. We investigated the glucuronidation of edaravone in human(More)
This paper considers the problem of non-parametric treatment comparisons when mixed interval-censored failure time data are available, which often occurs in clinical trials and epidemiological studies. By mixed interval-censored data, we mean that the survival time of interest is observed to belong to an interval or to be right-censored. For the problem, we(More)
AIMS To assess the effect of danshen extract on CYP3A4 activity using midazolam as an in vivo probe. METHODS A sequential, open-label, two-period pharmacokinetic interaction study design was used to compare midazolam pharmacokinetic parameters before and after 14 days of administration of danshen tablets. Twelve healthy volunteers received a single oral(More)